Separately, Zacks Investment Research raised shares of Amyris from a hold rating to a buy rating and set a $0.50 target price on the stock in a research report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amyris currently has a consensus rating of Buy and an average target price of $2.66.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm had revenue of $9.60 million for the quarter, compared to the consensus estimate of $15.23 million. The company’s revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.47) EPS.
A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock valued at $766,000 after buying an additional 311,142 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Amyris during the first quarter valued at approximately $269,000. Finally, Geode Capital Management LLC increased its stake in Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock valued at $331,000 after buying an additional 30,958 shares during the period. 35.68% of the stock is currently owned by institutional investors.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.